[go: up one dir, main page]

ATE276199T1 - Methoden zur herstellung von therapeutische kalzium-phosphat partikeln - Google Patents

Methoden zur herstellung von therapeutische kalzium-phosphat partikeln

Info

Publication number
ATE276199T1
ATE276199T1 AT00905941T AT00905941T ATE276199T1 AT E276199 T1 ATE276199 T1 AT E276199T1 AT 00905941 T AT00905941 T AT 00905941T AT 00905941 T AT00905941 T AT 00905941T AT E276199 T1 ATE276199 T1 AT E276199T1
Authority
AT
Austria
Prior art keywords
methods
calcium phosphate
biologically active
core particles
active material
Prior art date
Application number
AT00905941T
Other languages
English (en)
Inventor
Steve J D Bell
Claus Wagner-Bartak
Tulin Morcol
Qing He
Original Assignee
Biosante Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27382150&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE276199(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biosante Pharmaceuticals Inc filed Critical Biosante Pharmaceuticals Inc
Application granted granted Critical
Publication of ATE276199T1 publication Critical patent/ATE276199T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/062—Ascomycota
    • A61K36/064—Saccharomycetales, e.g. baker's yeast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5115—Inorganic compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Inorganic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Optics & Photonics (AREA)
  • Wood Science & Technology (AREA)
  • Pulmonology (AREA)
  • Nanotechnology (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Botany (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
AT00905941T 1999-02-03 2000-02-03 Methoden zur herstellung von therapeutische kalzium-phosphat partikeln ATE276199T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US11835599P 1999-02-03 1999-02-03
US11835699P 1999-02-03 1999-02-03
US11836499P 1999-02-03 1999-02-03
PCT/US2000/002742 WO2000046147A2 (en) 1999-02-03 2000-02-03 Therapeutic calcium phosphate particles and methods of manufacture and use

Publications (1)

Publication Number Publication Date
ATE276199T1 true ATE276199T1 (de) 2004-10-15

Family

ID=27382150

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00905941T ATE276199T1 (de) 1999-02-03 2000-02-03 Methoden zur herstellung von therapeutische kalzium-phosphat partikeln

Country Status (12)

Country Link
US (4) US6355271B1 (de)
EP (1) EP1150918B1 (de)
AT (1) ATE276199T1 (de)
AU (1) AU2753100A (de)
CA (1) CA2361421A1 (de)
DE (1) DE60013773T2 (de)
DK (1) DK1150918T3 (de)
ES (1) ES2228467T3 (de)
IL (2) IL144084A0 (de)
MX (1) MXPA01007895A (de)
PT (1) PT1150918E (de)
WO (1) WO2000046147A2 (de)

Families Citing this family (185)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6946198A (en) 1997-04-01 1998-10-22 Cap Biotechnology, Inc. Calcium phosphate microcarriers and microspheres
US20020192137A1 (en) * 2001-04-30 2002-12-19 Benjamin Chaloner-Gill Phosphate powder compositions and methods for forming particles with complex anions
US20030235557A1 (en) 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
ATE276199T1 (de) 1999-02-03 2004-10-15 Biosante Pharmaceuticals Inc Methoden zur herstellung von therapeutische kalzium-phosphat partikeln
US20020054914A1 (en) * 1999-02-03 2002-05-09 Tulin Morcol Compositions and methods for therapuetic agents complexed with calcium phosphate and encased by casein
US20020068090A1 (en) * 1999-02-03 2002-06-06 Bell Steve J. D. Calcium phosphate particles as mucosal adjuvants
US20040258763A1 (en) * 1999-02-03 2004-12-23 Bell Steve J.D. Methods of manufacture and use of calcium phosphate particles containing allergens
GB9910975D0 (en) * 1999-05-13 1999-07-14 Univ Strathclyde Rapid dehydration of proteins
ATE427751T1 (de) 1999-07-08 2009-04-15 Cap Biotechnology Inc Calcium-enthaltende strukture und verfahren zur herstellung und verwendung davon
DE10028975B4 (de) * 2000-06-16 2005-06-30 Henkel Kgaa Zusammensetzungen zur Behandlung von Zahn- und/oder Knochengewebe
AUPR011700A0 (en) 2000-09-14 2000-10-05 Austin Research Institute, The Composition comprising immunogenic virus sized particles (VSP)
WO2006073503A1 (en) * 2001-02-27 2006-07-13 Biosante Pharmaceuticals, Inc. Therapeutic calcium phosphate particles for use in inhibiting expression of a gene
GB0116074D0 (en) * 2001-06-29 2001-08-22 Univ Strathclyde Nanoparticle structures
IN192520B (de) * 2001-08-01 2004-04-24 Univ Delhi
US20030185892A1 (en) * 2001-08-17 2003-10-02 Bell Steve J. D. Intraocular delivery compositions and methods
ES2405405T3 (es) 2001-12-17 2013-05-31 Corixa Corporation Composiciones y procedimientos para la terapia y el diagnóstico de enfermedad inflamatoria del intestino
KR100976291B1 (ko) 2001-12-21 2010-08-16 알콘, 인코퍼레이티드 안과용 조성물중의 살생물제에 대한 담체로서 나노입자의용도
CA2467763C (en) 2001-12-21 2011-09-13 Alcon, Inc. Use of synthetic inorganic nanoparticles as carriers for ophthalmic and otic drugs
ES2397060T3 (es) * 2002-04-18 2013-03-04 Opko Pharmaceuticals, Llc Medios y métodos para la modulación específica de genes diana en el ojo
CN1674903A (zh) * 2002-07-11 2005-09-28 大鹏药品工业株式会社 经鼻吸收用组合物
US7148342B2 (en) 2002-07-24 2006-12-12 The Trustees Of The University Of Pennyslvania Compositions and methods for sirna inhibition of angiogenesis
WO2004065546A2 (en) 2003-01-16 2004-08-05 The Trustees Of The University Of Pennsylvania COMPOSITIONS AND METHODS FOR siRNA INHIBITION OF ICAM-1
EA015166B1 (ru) 2003-06-16 2011-06-30 Ю-Си-Би Мэньюфэкчуринг, Инк. Иммуногенные пептиды склеростина (sost), индуцирующие образование специфических антител
GB0324897D0 (en) * 2003-10-24 2003-11-26 Glaxo Group Ltd Composition
NZ546379A (en) * 2003-10-31 2010-04-30 Teva Pharma Nanoparticles for drug delivery
US8957034B2 (en) 2004-01-28 2015-02-17 Johns Hopkins University Drugs and gene carrier particles that rapidly move through mucous barriers
EP1720520B1 (de) 2004-02-13 2010-06-09 Nod Pharmaceuticals, Inc. Partikel mit kern aus calciumphosphat-nanopartikeln, biomolekül und gallensäure, herstellungsverfahren und therapeutische verwendung
WO2006050368A2 (en) 2004-11-01 2006-05-11 Biosante Pharmaceuticals, Inc. Therapeutic calcium phosphate particles iin use for aesthetic or cosmetic medicine, and methods of manufacture and use
KR101240883B1 (ko) 2004-11-16 2013-03-07 쓰리엠 이노베이티브 프로퍼티즈 컴파니 카제이네이트를 포함하는 치과용 충전제, 방법, 조성물
CN101098673B (zh) * 2004-11-16 2012-02-29 3M创新有限公司 包括磷酸盐的牙科填料和组合物
ZA200709003B (en) 2005-03-23 2009-05-27 Genmab As Antibodies against CD38 for treatment of multiple myeloma
FR2887457B1 (fr) * 2005-06-23 2007-10-05 Fond Bettencourt Schueller Vaccination par ciblage transcutane
JP4948806B2 (ja) 2005-08-09 2012-06-06 Ｈｏｙａ株式会社 粒子の製造方法
EP1931390B1 (de) * 2005-10-05 2012-07-25 Bayhill Therapeutics, Inc. Zusammensetzungen und verfahren zur behandlung von autoimmunkrankheit
EP1945249A2 (de) * 2005-11-01 2008-07-23 Novartis AG Zusammensetzungen mit an calciumphosphat adsorbierten antigenen
EP2368572B1 (de) 2005-11-04 2020-03-04 Seqirus UK Limited Adjuvansimpfstoffe mit nicht virenähnlichen Antigenen aus Influenza-Viren, die in einer Zellkultur gezüchtet wurden
PT1951299E (pt) 2005-11-04 2012-02-28 Novartis Vaccines & Diagnostic Vacinas contra a gripe que incluem combinações de adjuvantes particulados e imuno-potenciadores
UA95093C2 (uk) * 2005-12-07 2011-07-11 Нікомед Фарма Ас Спосіб одержання кальцієвмісної сполуки
KR20110110853A (ko) 2006-01-27 2011-10-07 노파르티스 파르마 아게 적혈구응집소 및 기질 단백질을 함유한 인플루엔자 백신
JP2009534303A (ja) 2006-03-24 2009-09-24 ノバルティス ヴァクシンズ アンド ダイアグノスティクス ゲーエムベーハー アンド カンパニー カーゲー 冷蔵しないインフルエンザワクチンの保存
US20100285062A1 (en) 2006-03-31 2010-11-11 Novartis Ag Combined mucosal and parenteral immunization against hiv
US20090130212A1 (en) * 2006-05-15 2009-05-21 Physical Pharmaceutica, Llc Composition and improved method for preparation of small particles
PT2054431E (pt) 2006-06-09 2011-11-03 Novartis Ag Confórmeros de adesinas bacterianas
EP2383341A1 (de) 2006-06-12 2011-11-02 Exegenics, Inc., D/b/a Opko Health, Inc. Zusammensetzungen und Verfahren zur SiRNA-Hemmung von Angiogenese
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
WO2008030383A2 (en) * 2006-09-06 2008-03-13 Boston Scientific Scimed, Inc. Medical devices having nanostructured coating for macromolecule delivery
WO2008030557A2 (en) * 2006-09-08 2008-03-13 Johns Hopkins University Compositions and methods for enhancing transport through mucus
US7872118B2 (en) * 2006-09-08 2011-01-18 Opko Ophthalmics, Llc siRNA and methods of manufacture
AU2007297178B2 (en) 2006-09-11 2014-07-24 Novartis Ag Making influenza virus vaccines without using eggs
US8946200B2 (en) * 2006-11-02 2015-02-03 Southwest Research Institute Pharmaceutically active nanosuspensions
CA2671629C (en) 2006-12-06 2017-08-15 Novartis Ag Vaccines including antigen from four strains of influenza virus
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
US20080241256A1 (en) * 2007-03-30 2008-10-02 Liisa Kuhn Targeted active agent delivery system based on calcium phosphate nanoparticles
GB0707938D0 (en) 2007-04-25 2007-05-30 Univ Strathclyde Precipitation stabilising compositions
AU2008269439B2 (en) 2007-06-27 2013-12-19 Novartis Ag Low-additive influenza vaccines
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
ES2399088T3 (es) 2007-11-01 2013-03-25 Perseid Therapeutics Llc Polipéptidos y ácidos nucleicos inmunosupresores
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
EP2229130A2 (de) * 2007-12-13 2010-09-22 3M Innovative Properties Company Remineralisierende zusammensetzungen und verfahren
GB0724498D0 (en) 2007-12-15 2008-01-30 Univ Strathclyde Slow release compositions
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
AU2008339631B2 (en) 2007-12-24 2014-07-24 Novartis Ag Assays for adsorbed influenza vaccines
TWI346666B (en) * 2007-12-31 2011-08-11 Animal Technology Inst Taiwan Method for seperating casein from casein-contained solution
EP2077273B1 (de) 2007-12-31 2011-09-14 Animal Technology Institute Taiwan Verfahren zur Trennung von Casein aus löslichen Proteinen in einer Zusammensetzung
US8404850B2 (en) * 2008-03-13 2013-03-26 Southwest Research Institute Bis-quaternary pyridinium-aldoxime salts and treatment of exposure to cholinesterase inhibitors
JP5518041B2 (ja) 2008-03-18 2014-06-11 ノバルティス アーゲー インフルエンザウイルスワクチン抗原の調製における改良
JP2011519867A (ja) 2008-05-01 2011-07-14 ノッド ファーマシューティカルズ， インコーポレイテッド 治療用リン酸カルシウム粒子、ならびにその作製および使用方法
US20110039947A1 (en) * 2008-05-08 2011-02-17 3M Innovative Properties Company Surface-modified nanoparticles
US8722706B2 (en) * 2008-08-15 2014-05-13 Southwest Research Institute Two phase bioactive formulations of bis-quaternary pyridinium oxime sulfonate salts
US8309134B2 (en) * 2008-10-03 2012-11-13 Southwest Research Institute Modified calcium phosphate nanoparticle formation
JP5832293B2 (ja) 2008-12-04 2015-12-16 オプコ ファーマシューティカルズ、エルエルシー 血管新生促進ｖｅｇｆイソ型を選択的に抑制する組成物および方法
UA109633C2 (uk) 2008-12-09 2015-09-25 Антитіло людини проти тканинного фактора
US8790707B2 (en) * 2008-12-11 2014-07-29 3M Innovative Properties Company Surface-treated calcium phosphate particles suitable for oral care and dental compositions
CN102438650A (zh) 2009-03-06 2012-05-02 诺华有限公司 衣原体抗原
RU2577698C2 (ru) 2009-03-26 2016-03-20 Пулмэтрикс, Инк. Сухие порошкообразные составы и способы лечения легочных заболеваний
NZ595689A (en) 2009-04-14 2014-03-28 Novartis Ag Compositions for immunising against staphylococcus aureus
KR20120027276A (ko) 2009-04-27 2012-03-21 노파르티스 아게 인플루엔자를 예방하기 위한 면역증강된 백신
US8574589B2 (en) 2009-05-11 2013-11-05 Novartis Ag Antigen purification process for pertactin antigen
SG177533A1 (en) 2009-07-07 2012-02-28 Novartis Ag Conserved escherichia coli immunogens
AR077757A1 (es) 2009-07-15 2011-09-21 Novartis Ag Composiciones de proteinas de fusion del virus sincicial respiratorio (rsv) y metodos para su preparacion
CA2768343A1 (en) 2009-07-16 2011-01-20 Novartis Ag Detoxified escherichia coli immunogens
US9937128B2 (en) 2009-08-03 2018-04-10 The University Of North Carolina At Chapel Hill Liposomes comprising a calcium phosphate-containing precipitate
WO2011030682A1 (ja) * 2009-09-09 2011-03-17 国立大学法人東京工業大学 ウイルス外殻構成タンパク質被覆構造体及びその製造方法
GB0918392D0 (en) 2009-10-20 2009-12-02 Novartis Ag Diagnostic and therapeutic methods
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
WO2011069155A1 (en) * 2009-12-04 2011-06-09 Opko Ophthalmics, Llc Compositions and methods for inhibition of vegf
EP2519265B1 (de) 2009-12-30 2018-11-14 GlaxoSmithKline Biologicals SA An e.coli-trägerproteine konjugierte polysaccharidimmunogene
US9028873B2 (en) * 2010-02-08 2015-05-12 Southwest Research Institute Nanoparticles for drug delivery to the central nervous system
EP2538929A4 (de) 2010-02-25 2014-07-09 Univ Johns Hopkins Verzögerte freisetzung von therapiemitteln in einen teil des auges
EA201201273A1 (ru) 2010-03-10 2013-02-28 Генмаб А/С Моноклональные антитела к с-мет
EP3539988A3 (de) 2010-05-27 2019-12-04 Genmab A/S Monoklonale antikörper gegen her2
CA2800769C (en) 2010-05-27 2021-11-02 Genmab A/S Monoclonal antibodies against her2 epitope
SI2580243T1 (sl) 2010-06-09 2020-02-28 Genmab A/S Protitelesa proti humanemu CD38
GB201009861D0 (en) 2010-06-11 2010-07-21 Novartis Ag OMV vaccines
EP3281956A3 (de) 2010-06-15 2018-04-18 Genmab A/S Menschliche antikörper-arzneimittelkonjugate gegen den gewebefaktor
US20130164338A1 (en) 2010-08-30 2013-06-27 Pulmatrix, Inc. Treatment of cystic fibrosis using calcium lactate, leucine and sodium chloride in a respiraple dry powder
CA2809666C (en) 2010-08-30 2020-09-22 Michael M. Lipp Dry powder formulations and methods for treating pulmonary diseases
GB201101665D0 (en) 2011-01-31 2011-03-16 Novartis Ag Immunogenic compositions
WO2012050945A1 (en) 2010-09-29 2012-04-19 Pulmatrix, Inc. Cationic dry powders
KR20180122475A (ko) 2010-09-29 2018-11-12 풀매트릭스 오퍼레이팅 컴퍼니, 인크 흡입용의 1가 금속 양이온 건조 분말
WO2012103361A1 (en) 2011-01-26 2012-08-02 Novartis Ag Rsv immunization regimen
WO2012109363A2 (en) 2011-02-08 2012-08-16 The Johns Hopkins University Mucus penetrating gene carriers
US9499610B2 (en) 2011-04-08 2016-11-22 H. Lundbeck A/S Antibodies specific to pyroglutamated Aβ
AU2012245116A1 (en) 2011-04-20 2013-11-07 Genmab A/S Bispecific antibodies against HER2 and CD3
CN103796678B (zh) 2011-04-20 2018-02-27 健玛保 针对her2的双特异性抗体
HUE034673T2 (en) 2011-05-13 2018-02-28 Glaxosmithkline Biologicals Sa Pre-fusion rsv f antigens
EP2723365A1 (de) 2011-06-21 2014-04-30 Oncofactor Corporation Zusammensetzungen und verfahren zur behandlung und diagnose von krebs
US9149541B2 (en) 2011-07-08 2015-10-06 Novartis Ag Tyrosine ligation process
RS59166B1 (sr) 2011-10-27 2019-10-31 Genmab As Proizvodnja heterodimernih proteina
WO2013068949A1 (en) 2011-11-07 2013-05-16 Novartis Ag Carrier molecule comprising a spr0096 and a spr2021 antigen
RU2472471C1 (ru) * 2011-11-24 2013-01-20 Федеральное государственное бюджетное учреждение "Московский научно-исследовательский институт глазных болезней имени Гельмгольца" Министерства здравоохранения и социального развития Российской Федерации Способ снижения внутриглазного давления
JP2015500864A (ja) 2011-12-23 2015-01-08 ノバルティス アーゲー 黄色ブドウ球菌（Ｓｔａｐｈｙｌｏｃｏｃｃｕｓａｕｒｅｕｓ）に対して免疫するための安定な組成物
CN104487075A (zh) 2012-02-29 2015-04-01 普马特里克斯公司 可吸入干粉剂
JP5883539B2 (ja) 2012-03-16 2016-03-15 ザ・ジョンズ・ホプキンス・ユニバーシティー Ｈｉｆ−１阻害剤の送達のための放出制御製剤
US10159743B2 (en) 2012-03-16 2018-12-25 The Johns Hopkins University Non-linear multiblock copolymer-drug conjugates for the delivery of active agents
US9827191B2 (en) 2012-05-03 2017-11-28 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
EP4008355A1 (de) 2012-05-03 2022-06-08 Kala Pharmaceuticals, Inc. Pharmazeutische nanopartikel mit verbessertem mukosalem transport
CA2871745C (en) 2012-05-03 2023-01-24 Kala Pharmaceuticals, Inc. Pharmaceutical nanoparticles showing improved mucosal transport
US11596599B2 (en) 2012-05-03 2023-03-07 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
US9533068B2 (en) 2012-05-04 2017-01-03 The Johns Hopkins University Drug loaded microfiber sutures for ophthalmic application
CN104736174B (zh) 2012-07-06 2019-06-14 根马布私人有限公司 具有三重突变的二聚体蛋白质
US20150203543A1 (en) 2012-08-31 2015-07-23 Novartis Ag Stabilised proteins for immunising against staphylococcus aureus
PT2890394T (pt) 2012-08-31 2019-07-15 Glaxosmithkline Biologicals Sa Proteínas estabilizadas para imunização contra staphylococcus aureus
MX2015004171A (es) 2012-10-02 2015-10-22 Glaxosmithkline Biolog Sa Conjugados de sacaridos no lineales.
RU2015106745A (ru) 2012-10-03 2016-11-27 Глэксосмитклайн Байолоджикалз Са Иммуногенные композиции
WO2014064710A1 (en) 2012-10-22 2014-05-01 Department Of Biotechnology A process for the prepartion of non-viral vector for delivery of nucleic acids by mucosal route
EP3345617B1 (de) 2012-11-30 2020-08-26 GlaxoSmithKline Biologicals S.A. Pseudomonas-antigene und antigen-kombinationen
WO2014124006A1 (en) 2013-02-05 2014-08-14 The Johns Hopkins University Nanoparticles for magnetic resonance imaging tracking and methods of making and using thereof
US9353122B2 (en) 2013-02-15 2016-05-31 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
CN107915751A (zh) 2013-02-20 2018-04-17 卡拉制药公司 治疗性化合物和其用途
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
JP6473738B2 (ja) 2013-04-01 2019-02-20 パルマトリックス，インコーポレイテッド チオトロピウム乾燥粉末
PL3016681T3 (pl) 2013-07-05 2020-06-15 Genmab A/S Humanizowane lub chimeryczne przeciwciała CD3
AU2013401479B2 (en) * 2013-09-26 2019-04-04 BioNTech SE Particles comprising a shell with RNA
US9458169B2 (en) 2013-11-01 2016-10-04 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
EP2870974A1 (de) 2013-11-08 2015-05-13 Novartis AG Salmonella-Konjugatimpfstoffe
KR102027429B1 (ko) 2014-03-26 2019-10-01 글락소스미스클라인 바이오로지칼즈 에스.에이. 돌연변이 스태필로코쿠스 항원
US10132818B2 (en) 2014-07-08 2018-11-20 New York University Tau imaging ligands and their uses in the diagnosis and treatment of tauopathy
DK3169706T3 (da) 2014-07-11 2020-03-09 Genmab As Antistoffer, der binder axl
ES2557183B1 (es) * 2014-07-21 2016-11-03 Consejo Superior De Investigaciones Científicas (Csic) Procedimiento de obtención de nanopartículas de fosfato de calcio amorfo recubiertas de citrato y dopadas con flúor
CN107635545A (zh) 2015-01-27 2018-01-26 约翰霍普金斯大学 用于增强粘膜表面处活性剂的输送的低渗水凝胶制剂
JP6892431B2 (ja) 2015-07-10 2021-06-23 ゲンマブ エー／エス 癌治療用のａｘｌ特異的抗体−薬物コンジュゲート
JO3711B1 (ar) 2015-07-13 2021-01-31 H Lundbeck As أجسام مضادة محددة لبروتين تاو وطرق استعمالها
GB201512215D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
ES2954969T3 (es) 2015-08-13 2023-11-27 Univ New York Moléculas basadas en anticuerpos selectivas para el epítopo {p}Ser404 de Tau y sus usos en el diagnóstico y tratamiento de la tauopatía
CN109476737A (zh) 2015-12-01 2019-03-15 根马布有限公司 抗dr5抗体及其使用方法
MY197836A (en) 2016-07-12 2023-07-20 H Lundbeck As Antibodies specific for hyperphosphorylated tau and methods of use thereof
US11091557B2 (en) 2016-07-14 2021-08-17 Genmab A/S Methods of producing multispecific antibodies against CD40 and CD137
EP3509423A4 (de) 2016-09-08 2020-05-13 Kala Pharmaceuticals, Inc. Kristalline formen von therapeutischen verbindungen und verwendungen davon
AU2017324713B2 (en) 2016-09-08 2020-08-13 KALA BIO, Inc. Crystalline forms of therapeutic compounds and uses thereof
CA3036065A1 (en) 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
RU2657780C2 (ru) * 2016-09-14 2018-06-15 Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) Средство для лечения глазных заболеваний и способ его применения
JP7144755B2 (ja) 2016-12-16 2022-09-30 ハー・ルンドベック・アクチエゼルスカベット 薬剤、使用および方法
US11938456B2 (en) 2016-12-16 2024-03-26 Delphi Scientific, Llc Layered particles and processes thereof
US10995137B2 (en) 2017-01-04 2021-05-04 H. Lundbeck A/S Antibodies specific for hyperphosphorlated tau for the treatment of ocular diseases
EP3592769B1 (de) 2017-03-09 2024-05-08 Genmab A/S Antikörper gegen pd-l1
CA3057907A1 (en) 2017-03-31 2018-10-04 Genmab Holding B.V. Bispecific anti-cd37 antibodies, monoclonal anti-cd37 antibodies and methods of use thereof
EP3635005A1 (de) 2017-06-07 2020-04-15 Genmab B.V. Therapeutische antikörper auf der basis von mutierten igg-hexameren
US10894833B2 (en) 2017-07-20 2021-01-19 H. Lundbeck A/S Agents, uses and methods for treatment
CN116333131A (zh) 2017-08-04 2023-06-27 健玛保 与pd-l1和cd137结合的结合剂及其用途
SG11202008399QA (en) 2018-03-12 2020-09-29 Genmab As Antibodies
WO2019243636A1 (en) 2018-06-22 2019-12-26 Genmab Holding B.V. Anti-cd37 antibodies and anti-cd20 antibodies, compositions and methods of use thereof
WO2020012038A1 (en) 2018-07-13 2020-01-16 Genmab A/S Trogocytosis-mediated therapy using cd38 antibodies
CA3106146A1 (en) 2018-07-13 2020-01-16 Genmab A/S Variants of cd38 antibody and uses thereof
SG11202103100SA (en) 2018-10-04 2021-04-29 Genmab Holding B V Pharmaceutical compositions comprising bispecific anti-cd37 antibodies
BR112021007668A2 (pt) 2018-11-06 2021-07-27 Glaxosmithkline Biologicals S.A. composições imunogênicas
WO2020257315A1 (en) * 2019-06-18 2020-12-24 Citranvi Biosciences, Llc Multiple antigen protein displayed adjuvant systems
KR20220154757A (ko) 2020-03-18 2022-11-22 젠맵 에이/에스 B7h4에 결합하는 항체
CU20200032A7 (es) * 2020-06-09 2022-01-13 Ct Inmunologia Molecular Composiciones vacunales basadas en nano-partículas de fosfatos de calcio para el tratamiento del cáncer
CA3192251A1 (en) 2020-09-10 2022-03-17 Genmab A/S Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma
CN116437956A (zh) 2020-09-10 2023-07-14 健玛保 用于治疗慢性淋巴细胞白血病的针对cd3和cd20的双特异性抗体
WO2022069724A1 (en) 2020-10-02 2022-04-07 Genmab A/S Antibodies capable of binding to ror2 and bispecific antibodies binding to ror2 and cd3
WO2022148413A1 (zh) 2021-01-08 2022-07-14 北京韩美药品有限公司 特异性结合4-1bb的抗体及其抗原结合片段
JP2024503396A (ja) 2021-01-08 2024-01-25 北京韓美薬品有限公司 Ｃｄ４７と特異的に結合する抗体及びその抗原結合フラグメント
US20240301068A1 (en) 2021-01-08 2024-09-12 Beijing Hanmi Pharmaceutical Co., Ltd. Antibody specifically binding with pd-l1 and antigen-binding fragment of antibody
EP4305056A1 (de) 2021-03-12 2024-01-17 Genmab A/S Nicht aktivierende antikörpervarianten
WO2022261251A1 (en) 2021-06-08 2022-12-15 Glyde Bio Inc. Immunogenic compositions comprising tumour-associated antigen
AU2022338208A1 (en) 2021-09-06 2024-03-21 Genmab A/S Antibodies capable of binding to cd27, variants thereof and uses thereof
AR127298A1 (es) 2021-10-08 2024-01-10 Genmab As Anticuerpos que se unen a cd30 y cd3
WO2024102948A1 (en) 2022-11-11 2024-05-16 Celgene Corporation Fc receptor-homolog 5 (fcrh5) specific binding molecules and bispecific t-cell engaging antibodies including same and related methods
WO2024208898A1 (en) 2023-04-05 2024-10-10 Genmab A/S Pharmaceutical compositions comprising antibodies binding to cd30 and cd3
WO2024235862A1 (en) 2023-05-12 2024-11-21 Genmab A/S Antibodies capable of binding to ox40, variants thereof and uses thereof
US20250002610A1 (en) 2023-06-30 2025-01-02 Genmab A/S Antibodies binding to fibroblast activation protein alpha and death receptor 4

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3183545A (en) 1961-06-29 1965-05-18 Bergstrom Eric Victor Easy slide caster
AU407324B2 (en) 1962-05-01 1970-10-28 Smith, Kline & French Laboratories Powdered silicone products and processes
FR2181426B1 (de) 1972-04-06 1974-12-20 Pasteur Institut
US4016252A (en) 1972-04-06 1977-04-05 Institut Pasteur Calcium phosphate gel for adsorbing vaccines
US4070454A (en) * 1973-05-04 1978-01-24 Agence Nationale De Valorisation De La Recherche (Anvar) Vaccines, the process for preparing the same and the applications thereof
FR2227861B1 (de) * 1973-05-04 1976-07-02 Anvar
FR2466991A1 (fr) 1979-10-08 1981-04-17 Pasteur Institut Perfectionnement a la preparation d'allergene
FR2505657A1 (fr) 1981-05-13 1982-11-19 Pasteur Institut Perfectionnements apportes aux agents de stabilisation de virus vivants pour la preparation de vaccins, et vaccins stabilises contenant lesdits agents de stabilisation
FR2522269A1 (fr) * 1982-02-26 1983-09-02 Pasteur Institut Agents antitumoraux, tels que la daunorubicine, a efficacite amelioree, leur obtention et procede pour augmenter l'efficacite des agents antitumoraux
US4963526A (en) 1984-05-09 1990-10-16 Synthetic Blood Corporation Oral insulin and a method of making the same
FR2577048B1 (fr) * 1985-02-05 1988-05-06 Pasteur Institut Reactif pour le dosage par hemagglutination des anticorps contre les toxines bacteriennes, procede de preparation et son application
US4683195A (en) * 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) * 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
CA1291036C (en) 1986-04-23 1991-10-22 Edwin I. Stoltz Nasal administration of drugs
US4983341A (en) * 1987-12-28 1991-01-08 United Technologies Corporation Method of using breather materials for high pressure molding
IL88961A (en) 1988-01-29 1992-07-15 Basf Ag Stable mixtures containing oxidation-sensitive compounds
US5428066A (en) 1989-03-08 1995-06-27 Larner; Joseph Method of reducing elevated blood sugar in humans
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
DE69034078T2 (de) 1989-03-21 2004-04-01 Vical, Inc., San Diego Expression von exogenen Polynukleotidsequenzen in Wirbeltieren
US5441739A (en) 1990-06-22 1995-08-15 The Regents Of The University Of California Reduced and controlled surface binding of biologically active molecules
US5460830A (en) 1990-06-22 1995-10-24 The Regents Of The University Of California Biochemically active agents for chemical catalysis and cell receptor activation
US5462751A (en) 1990-06-22 1995-10-31 The Regeants Of The University Of California Biological and pharmaceutical agents having a nanomeric biodegradable core
US5464634A (en) 1990-06-22 1995-11-07 The Regents Of The University Of California Red blood cell surrogate
US5334394A (en) 1990-06-22 1994-08-02 The Regents Of The University Of California Human immunodeficiency virus decoy
US5178882A (en) 1990-06-22 1993-01-12 The Regents Of The University Of California Viral decoy vaccine
US5306508A (en) 1990-06-22 1994-04-26 The Regents Of The University Of California Red blood cell surrogate
US5460831A (en) 1990-06-22 1995-10-24 The Regents Of The University Of California Targeted transfection nanoparticles
US5219577A (en) 1990-06-22 1993-06-15 The Regents Of The University Of California Biologically active composition having a nanocrystalline core
US5110606A (en) * 1990-11-13 1992-05-05 Affinity Biotech, Inc. Non-aqueous microemulsions for drug delivery
US5462634A (en) * 1991-08-23 1995-10-31 Honda Giken Kogyo Kabushiki Kaisha Surface-treated aluminum material and method for its surface treatment
US6537574B1 (en) 1992-02-11 2003-03-25 Bioform, Inc. Soft tissue augmentation material
EP0627899B1 (de) 1992-02-28 2001-11-07 Cohesion Technologies, Inc. Injektierbare, keramische verbindungen sowie verfahren zur deren herstellung und anwendung
US5204382A (en) 1992-02-28 1993-04-20 Collagen Corporation Injectable ceramic compositions and methods for their preparation and use
DK0584348T3 (da) 1992-03-11 2005-09-19 Powderject Vaccines Inc Genetisk vaccine mod immundefektvirusser
US5620896A (en) 1992-03-23 1997-04-15 University Of Massachusetts Medical Center DNA vaccines against rotavirus infections
JP3285355B2 (ja) 1992-06-04 2002-05-27 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ｉｎｖｉｖｏ遺伝子治療のための方法及び組成物
WO1994008336A1 (en) * 1992-09-30 1994-04-14 Tdk Corporation Magnetic recording medium
FR2698560B1 (fr) * 1992-11-30 1995-02-03 Virbac Laboratoires Principes actifs pulvérulents stabilisés, compositions les contenant, leur procédé d'obtention et leurs applications.
US5364838A (en) 1993-01-29 1994-11-15 Miris Medical Corporation Method of administration of insulin
US5665382A (en) 1993-02-22 1997-09-09 Vivorx Pharmaceuticals, Inc. Methods for the preparation of pharmaceutically active agents for in vivo delivery
US5456986A (en) 1993-06-30 1995-10-10 Carnegie Mellon University Magnetic metal or metal carbide nanoparticles and a process for forming same
US5506203C1 (en) 1993-06-24 2001-02-06 Astra Ab Systemic administration of a therapeutic preparation
US5469599A (en) * 1993-10-27 1995-11-28 Wurdack; Roy A. Slide
IL113817A (en) 1994-06-30 2001-03-19 Merck & Co Inc Polynucleotide for vaccination against the umbilical cord virus
ATE257175T1 (de) * 1994-07-18 2004-01-15 Conzelmann Karl Klaus Prof Dr Rekombinantes infektiöses nicht-in-segmente- geteiltes, negativ-strange-rns-virus
CN1162148C (zh) * 1994-08-30 2004-08-18 阿尔康实验室公司 含有纤维素醚的热凝胶药物转运载体
WO1996006632A1 (en) * 1994-09-01 1996-03-07 Allied Medical Research Associates Compositions and methods for delivery of polypeptides
US5484720A (en) 1994-09-08 1996-01-16 Genentech, Inc. Methods for calcium phosphate transfection
US5789229A (en) * 1994-09-30 1998-08-04 Uab Research Foundation Stranded RNA virus particles
US5716821A (en) * 1994-09-30 1998-02-10 Uab Research Foundation Prevention and treatment of respiratory tract disease
US5858398A (en) * 1994-11-03 1999-01-12 Isomed Inc. Microparticular pharmaceutical compositions
DE4444052A1 (de) 1994-12-10 1996-06-13 Rhone Poulenc Rorer Gmbh Pharmazeutische, oral anwendbare Zubereitung
CA2207961A1 (en) 1995-01-05 1996-07-11 Robert J. Levy Surface-modified nanoparticles and method of making and using same
US5629021A (en) 1995-01-31 1997-05-13 Novavax, Inc. Micellar nanoparticles
US5747001A (en) 1995-02-24 1998-05-05 Nanosystems, L.L.C. Aerosols containing beclomethazone nanoparticle dispersions
IE80468B1 (en) 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
US6541037B1 (en) 1995-05-19 2003-04-01 Etex Corporation Delivery vehicle
US5676976A (en) 1995-05-19 1997-10-14 Etex Corporation Synthesis of reactive amorphous calcium phosphates
US8333996B2 (en) 1995-05-19 2012-12-18 Etex Corporation Calcium phosphate delivery vehicle and adjuvant
US5824638A (en) * 1995-05-22 1998-10-20 Shire Laboratories, Inc. Oral insulin delivery
US6579516B1 (en) * 1995-06-13 2003-06-17 Zahra Mansouri Methods of delivering materials into the skin, and compositions used therein
US5785975A (en) 1995-06-26 1998-07-28 Research Triangle Pharmaceuticals Adjuvant compositions and vaccine formulations comprising same
US5827822A (en) 1996-03-25 1998-10-27 Sangstat Medical Corporation Cyclosporin a formulations as nanoparticles
AU727923B2 (en) * 1995-09-27 2001-01-04 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Production of infectious respiratory syncytial virus from cloned nucleotide sequences
US5648097A (en) * 1995-10-04 1997-07-15 Biotek, Inc. Calcium mineral-based microparticles and method for the production thereof
US5695617A (en) 1995-11-22 1997-12-09 Dow Corning Corporation Silicon nanoparticles
US5869036A (en) * 1995-12-08 1999-02-09 St. Louis University Live attenuated vaccines based on CP45 HPIV-3 strain and method to ensure attenuation in such vaccine
US5985312A (en) * 1996-01-26 1999-11-16 Brown University Research Foundation Methods and compositions for enhancing the bioadhesive properties of polymers
JPH09205491A (ja) 1996-01-26 1997-08-05 Nec Telecom Syst Ltd Ｉｓｄｎテレメータリング方式
GB9602797D0 (en) * 1996-02-12 1996-04-10 Unilever Plc Inorganic material in particles form
US5955096A (en) * 1996-06-25 1999-09-21 Brown University Research Foundation Methods and compositions for enhancing the bioadhesive properties of polymers using organic excipients
JPH10114897A (ja) 1996-10-11 1998-05-06 Sangi Co Ltd 粉末香料、その製造方法及びその応用
WO1998020389A1 (en) * 1996-11-08 1998-05-14 Optical Coating Laboratory, Inc. Coated flexible glass films for visual display units
AU722326B2 (en) * 1997-02-14 2000-07-27 Merck & Co., Inc. Polynucleotide vaccine formulations
US5898028A (en) 1997-03-20 1999-04-27 Novo Nordisk A/S Method for producing powder formulation comprising an insulin
AU6946198A (en) * 1997-04-01 1998-10-22 Cap Biotechnology, Inc. Calcium phosphate microcarriers and microspheres
US5891420A (en) 1997-04-21 1999-04-06 Aeropharm Technology Limited Environmentally safe triancinolone acetonide aerosol formulations for oral inhalation
AU3860797A (en) 1997-07-16 1999-02-10 Antrin Research Limited Pharmaceutical formulations for oral administration
US6187335B1 (en) 1997-12-31 2001-02-13 Orasomal Technologies, Inc. Polymerizable fatty acids, phospholipids and polymerized liposomes therefrom
US6017545A (en) 1998-02-10 2000-01-25 Modi; Pankaj Mixed micellar delivery system and method of preparation
US6251474B1 (en) * 1998-11-06 2001-06-26 Idaho Research Foundation Method of producing substantially spherical magneto-plumbite ferrite particles
US20020054914A1 (en) 1999-02-03 2002-05-09 Tulin Morcol Compositions and methods for therapuetic agents complexed with calcium phosphate and encased by casein
US20040258763A1 (en) 1999-02-03 2004-12-23 Bell Steve J.D. Methods of manufacture and use of calcium phosphate particles containing allergens
ATE276199T1 (de) * 1999-02-03 2004-10-15 Biosante Pharmaceuticals Inc Methoden zur herstellung von therapeutische kalzium-phosphat partikeln
US20020068090A1 (en) 1999-02-03 2002-06-06 Bell Steve J. D. Calcium phosphate particles as mucosal adjuvants
US6183803B1 (en) 1999-06-11 2001-02-06 Biosante Pharmaceuticals, Inc. Method for processing milk
US6183335B1 (en) * 1999-12-10 2001-02-06 Christine Petersen Suspended display arrangement for vehicles
JP2001302431A (ja) 2000-04-21 2001-10-31 Mitsui Chemicals Inc リン酸カルシウム微粒子を含有する化粧料
WO2006073503A1 (en) 2001-02-27 2006-07-13 Biosante Pharmaceuticals, Inc. Therapeutic calcium phosphate particles for use in inhibiting expression of a gene
US20030185892A1 (en) 2001-08-17 2003-10-02 Bell Steve J. D. Intraocular delivery compositions and methods
WO2004026453A2 (en) 2002-09-06 2004-04-01 Genteric, Inc. Microcapsules and methods of use

Also Published As

Publication number Publication date
DE60013773T2 (de) 2005-11-10
US20110236685A1 (en) 2011-09-29
AU2753100A (en) 2000-08-25
DE60013773D1 (de) 2004-10-21
MXPA01007895A (es) 2003-07-21
US8431221B2 (en) 2013-04-30
WO2000046147A3 (en) 2000-12-07
DK1150918T3 (da) 2004-12-20
PT1150918E (pt) 2005-01-31
CA2361421A1 (en) 2000-08-10
ES2228467T3 (es) 2005-04-16
IL144084A (en) 2006-10-31
EP1150918A2 (de) 2001-11-07
WO2000046147A2 (en) 2000-08-10
US20070292454A1 (en) 2007-12-20
US6355271B1 (en) 2002-03-12
US20010048925A1 (en) 2001-12-06
EP1150918B1 (de) 2004-09-15
IL144084A0 (en) 2002-05-23

Similar Documents

Publication Publication Date Title
DE60013773D1 (de) Methoden zur herstellung von therapeutische kalzium-phosphat partikeln
DE69840495D1 (de) Darreichungsform, welche rasche dispersionseigenschaften entfaltet, anwendungsverfahren sowie verfahren zur herstellung derselben
DE69518910D1 (de) Verfahren zur herstellung von viralen vektoren von mindestens 20kb durch intermolekulare homologe rekombination in einer prokaryotischen zelle
WO2002026162A3 (en) A method of loading a substance onto an implantable device
DE60232061D1 (de) Poröse beta-tricalciumphosphat-körnchen und ein herstellungsverfahren
EP0158277A3 (de) Implantierbare Zubereitungen von regulatorischen Peptiden mit gesteuerter Freisetzung und Verfahren zur ihrer Herstellung
RU94045951A (ru) Покровный материал и способ его получения, имплантант для биомедицинского использования
GEP20032976B (en) Artificial Peptides Having Surface Activity and Use Thereof in The Preparation of Artificial Surfactant
EP1710311A3 (de) Antigene Polypeptide
ATE65386T1 (de) Verwendung von poroesen fuellstoffen in polymerisierbaren dentalmassen, solche massen und deren verwendung zur herstellung von formkoerpern.
DE69530086D1 (de) Aufnahme von biologisch aktiven molekülen in bioaktives glas
ATE198982T1 (de) Verfahren zur herstellung von festen pharmazeutischen dosierungsformen hydrophobischen substanzen
WO2001034801A3 (en) Recombinant gelatin in vaccines
EP0269745A4 (de) Knochenimplantat.
DE60011243D1 (de) Verfahren zur herstellung von mit antioxidant gedoptem uhmwpe und daraus hergestelltes implantat
CA2098814A1 (en) Method of producing microscopic particles made of hydrolytically decomposable polymers and containing active substances
FI933328A0 (fi) Antigen producerande protein
ATE233097T1 (de) Verfahren zur herstellung von igf-i formulierungen mit verzögerter freisetzung
IL125590A (en) Peptide immunogens, process for their preparation and use thereof as vaccines against allergies
EP0923955A3 (de) Verfahren zur Herstellung eines künstliches Organs, Hohlfasermembran, und Hohlfaserdialysator
ATE293438T1 (de) Dämpfwachsperlen zur herstellung von festen formgegenständen
DE69001573D1 (de) Zusammensetzungen zur herstellung von in dosisformen aktiven vitaminen d3 sowie verfahren zur herstellung stabiler, in dosisformen aktiver vitamine d3 unter deren verwendung.
DE69703083D1 (de) Verfahren zur Herstellung von feinen kugelförmigen Yttriumoxidteilchen
DE60204125D1 (de) Verfahren zur herstellung von metoprolol enthaltenden mikropartikeln
DE69904142D1 (de) Verfahren zur herstellung von im wesentlichen sphärischen lyo-gelen in wasserunlöslischen silylierungsmitteln

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1150918

Country of ref document: EP

REN Ceased due to non-payment of the annual fee